Evidence map›Paper›PMID 32661794›Full record

ReviewNeurocritical care2021

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review.

Ghazal Aghagoli, Benjamin Gallo Marin, Nicole J Katchur, Franz Chaves-Sell, Wael F Asaad, Sarah A Murphy

Open access · bronzeAbstract readReview
In one paragraph

Review in Neurocritical care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 7 pooled it
26.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 7 syntheses or guidelines pooled it, 358 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Ghazal AghagoliWarren Alpert Medical School of Brown University, Providence, RI, USA. ghazal_aghagoli@brown.edu.ORCID http://orcid.org/0000-0003-3322-9672
Benjamin Gallo MarinWarren Alpert Medical School of Brown University, Providence, RI, USA.
Nicole J KatchurRobert Wood Johnson Medical School, Piscataway, NJ, USA.
Franz Chaves-SellDepartamento de Neurología, Hospital Clínica Bíblica, San José, Costa Rica.
Wael F AsaadWarren Alpert Medical School of Brown University, Providence, RI, USA.
Sarah A MurphyHarvard Medical School, Boston, MA, USA.
Brown University · USAllen Institute for Brain Science · USBoston University · USJohnson University · USUniversidad Bíblica Latinoamericana · CR

Funding

Emerging Infectious Disease Scholars at Brown UniversityR25AI140490 · NIAID · BROWN UNIVERSITY · PI Silvia Shinpei Chiang · 2018 to 2026
$3.0M
National Institute of Allergy and Infectious Diseases R25AI140490NIAID NIH HHS R25 AI140490
6 · The paper itself

Abstract

As the current understanding of COVID-19 continues to evolve, a synthesis of the literature on the neurological impact of this novel virus may help inform clinical management and highlight potentially important avenues of investigation. Additionally, understanding the potential mechanisms of neurologic injury may guide efforts to better detect and ameliorate these complications. In this review, we synthesize a range of clinical observations and initial case series describing potential neurologic manifestations of COVID-19 and place these observations in the context of coronavirus neuro-pathophysiology as it may relate to SARS-CoV-2 infection. Reported nervous system manifestations range from anosmia and ageusia, to cerebral hemorrhage and infarction. While the volume of COVID-19-related case studies continues to grow, previous work examining related viruses suggests potential mechanisms through which the novel coronavirus may impact the CNS and result in neurological complications. Namely, animal studies examining the SARS-CoV have implicated the angiotensin-converting-enzyme-2 receptor as a mediator of coronavirus-related neuronal damage and have shown that SARS-CoV can infect cerebrovascular endothelium and brain parenchyma, the latter predominantly in the medial temporal lobe, resulting in apoptosis and necrosis. Human postmortem brain studies indicate that human coronavirus variants and SARS-CoV can infect neurons and glia, implying SARS-CoV-2 may have similar neurovirulence. Additionally, studies have demonstrated an increase in cytokine serum levels as a result of SARS-CoV infection, consistent with the notion that cytokine overproduction and toxicity may be a relevant potential mechanism of neurologic injury, paralleling a known pathway of pulmonary injury. We also discuss evidence that suggests that SARS-CoV-2 may be a vasculotropic and neurotropic virus. Early reports suggest COVID-19 may be associated with severe neurologic complications, and several plausible mechanisms exist to account for these observations. A heightened awareness of the potential for neurologic involvement and further investigation into the relevant pathophysiology will be necessary to understand and ultimately mitigate SARS-CoV-2-associated neurologic injury.

Indexed as

COVID-19HumansNervous System DiseasesSARS-CoV-2Cerebrovascular strokeCoronavirusInflammationNeurology

Identifiers

PMID32661794
PMCPMC7358290
OpenAlexW3042862995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.